Catalog No.
EVV24301
Expression system
Mammalian Cells
Species
Lake Victoria marburgvirus (strain Ravn-87) (MARV) (Marburg virus (strain Kenya/Ravn/1987))
Protein length
Leu19-Gly650
Predicted molecular weight
73.08 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q1PDC7
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Envelope glycoprotein, GP1,2, GP, Virion spike glycoprotein, GP1, GP2, GP
MyosinVb tail inhibits transport of Marburg virus glycoprotein GP to VP40-enriched sites at the plasma membrane., PMID:40174331
From protein to immunology: comprehensive insights into Marburg virus vaccines, mechanism, and application., PMID:40025302
Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans., PMID:39771978
A surrogate BSL2-compliant infection model recapitulating key aspects of human Marburg virus disease., PMID:39745141
Serological Evidence of Potential Marburg Virus Circulation in Livestock and Dogs in Ghana., PMID:39599470
In Vivo Investigation of Filovirus Glycoprotein-Mediated Infection in a BSL2 Setting., PMID:39585622
Lysosome-Associated Membrane Protein Targeting Strategy Improved Immunogenicity of Glycoprotein-Based DNA Vaccine for Marburg Virus., PMID:39340043
Longitudinal proteome-wide antibody profiling in Marburg virus survivors identifies wing domain immunogen for vaccine design., PMID:39285186
Rational design of self-amplifying virus-like vesicles with Ebola virus glycoprotein as vaccines., PMID:39217415
A novel MARV glycoprotein-specific antibody with potentials of broad-spectrum neutralization to filovirus., PMID:38526940
Production and Purification of Filovirus Glycoproteins., PMID:38315357
Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection., PMID:38158300
Designing a novel and combinatorial multi-antigenic epitope-based vaccine "MarVax" against Marburg virus-a reverse vaccinology and immunoinformatics approach., PMID:38012426
Preexisting Immunity Does Not Prevent Efficacy of Vesicular Stomatitis Virus-Based Filovirus Vaccines in Nonhuman Primates., PMID:37290042
The Inability of Marburg Virus to Cause Disease in Ferrets Is Not Solely Linked to the Virus Glycoprotein., PMID:37288605
Structural and Energetic Basis for Differential Binding of Ebola and Marburg Virus Glycoproteins to a Bat-Derived Niemann-Pick C1 Protein., PMID:37119290
Chaperoning the driver of filovirus egress to a dead end., PMID:36763514
A rabies virus-vectored vaccine expressing two copies of the Marburg virus glycoprotein gene induced neutralizing antibodies against Marburg virus in humanized mice., PMID:36453198
First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study., PMID:36197845
Ligand-based design of peptide entry inhibitors targeting the endosomal receptor binding site of filoviruses., PMID:36007601
Marburg Virus VP30 Is Required for Transcription Initiation at the Glycoprotein Gene., PMID:35997284
Mining of Marburg Virus Proteome for Designing an Epitope-Based Vaccine., PMID:35911751
A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge., PMID:35622847
Comparative analyses of small molecule and antibody inhibition on glycoprotein-mediated entry of Měnglà virus with other filoviruses., PMID:35332563
Protein disulfide isomerases (PDIs) negatively regulate ebolavirus structural glycoprotein expression in the endoplasmic reticulum (ER) via the autophagy-lysosomal pathway., PMID:35130104
Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses., PMID:34484200
Prototype of a DNA Vaccine against Marburg Virus., PMID:33713231
Identification of filovirus entry inhibitors targeting the endosomal receptor NPC1 binding site., PMID:33705865
Ebola virus triggers receptor tyrosine kinase-dependent signaling to promote the delivery of viral particles to entry-conducive intracellular compartments., PMID:33513206
Discovery of Marburg virus neutralizing antibodies from virus-naïve human antibody repertoires using large-scale structural predictions., PMID:33229516
Receptor-Mediated Host Cell Preference of a Bat-Derived Filovirus, Lloviu Virus., PMID:33027954
Modified vaccinia Ankara vaccine expressing Marburg virus-like particles protects guinea pigs from lethal Marburg virus infection., PMID:32922962
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors., PMID:32886512
A Surrogate Animal Model for Screening of Ebola and Marburg Glycoprotein-Targeting Drugs Using Pseudotyped Vesicular Stomatitis Viruses., PMID:32842671
Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies., PMID:32320678
Immune correlates of postexposure vaccine protection against Marburg virus., PMID:32080323
Niemann-Pick C1 Heterogeneity of Bat Cells Controls Filovirus Tropism., PMID:31940478
Marburg virus regulates the IRE1/XBP1-dependent unfolded protein response to ensure efficient viral replication., PMID:31495285
Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation., PMID:30723475
A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model., PMID:30567978
Identity and validity of conserved B cell epitopes of filovirus glycoprotein: towards rapid diagnostic testing for Ebola and possibly Marburg virus disease., PMID:30285648
A Fluorescently Labeled Marburg Virus Glycoprotein as a New Tool to Study Viral Transport and Assembly., PMID:30165666
Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors., PMID:30107445
Lectin Affinity Plasmapheresis for Middle East Respiratory Syndrome-Coronavirus and Marburg Virus Glycoprotein Elimination., PMID:29698959
Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge., PMID:29142131
Marburg virus-like particles by co-expression of glycoprotein and matrix protein in insect cells induces immune responses in mice., PMID:29070075
Marburg virus-like particles produced in insect cells induce neutralizing antibodies in rhesus macaques., PMID:28402024
Generation and characterization of protective antibodies to Marburg virus., PMID:28287337
Toremifene interacts with and destabilizes the Ebola virus glycoprotein., PMID:27362232
Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses., PMID:27335383
For research use only. Not for human or drug use.
